Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Raymond Taeyong Chung, M.D.

Co-Author

This page shows the publications co-authored by Raymond Chung and Todd Allen.
Connection Strength

0.952
  1. Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A synthase. J Infect Dis. 2011 Aug 15; 204(4):609-16.
    View in: PubMed
    Score: 0.119
  2. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008 Dec; 48(6):1769-78.
    View in: PubMed
    Score: 0.099
  3. Viral sequence evolution in acute hepatitis C virus infection. J Virol. 2007 Nov; 81(21):11658-68.
    View in: PubMed
    Score: 0.090
  4. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology. 2007 Aug; 46(2):339-49.
    View in: PubMed
    Score: 0.090
  5. Characterization of full-length hepatitis C virus genotype 4 sequences. J Viral Hepat. 2007 May; 14(5):330-7.
    View in: PubMed
    Score: 0.088
  6. CD8 epitope escape and reversion in acute HCV infection. J Exp Med. 2004 Dec 20; 200(12):1593-604.
    View in: PubMed
    Score: 0.075
  7. Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory. Nat Immunol. 2021 08; 22(8):1030-1041.
    View in: PubMed
    Score: 0.059
  8. Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. Nat Immunol. 2021 08; 22(8):1020-1029.
    View in: PubMed
    Score: 0.059
  9. Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection. Immunity. 2017 10 17; 47(4):648-663.e8.
    View in: PubMed
    Score: 0.046
  10. The epigenetic landscape of T cell exhaustion. Science. 2016 12 02; 354(6316):1165-1169.
    View in: PubMed
    Score: 0.043
  11. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med. 2012 Jan 16; 209(1):61-75.
    View in: PubMed
    Score: 0.031
  12. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology. 2011 Feb; 140(2):686-696.e1.
    View in: PubMed
    Score: 0.028
  13. High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol. 2008 Mar; 82(6):3154-60.
    View in: PubMed
    Score: 0.023
  14. Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood. 2007 Sep 01; 110(5):1559-69.
    View in: PubMed
    Score: 0.022
  15. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 2006 Dec; 3(12):e492.
    View in: PubMed
    Score: 0.021
  16. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol. 2005 Oct; 79(20):12979-88.
    View in: PubMed
    Score: 0.020
  17. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol. 2005 Sep 15; 175(6):3603-13.
    View in: PubMed
    Score: 0.020
  18. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology. 2004 Sep; 127(3):924-36.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.